- Acıbadem Üniversitesi Sağlık Bilimleri Dergisi
- Vol: 12 Issue: 2
- Kronik Lenfositik Lösemide PD-1/PD-L1 Ekspresyon Düzeyleri ve Prognostik Önemi
Kronik Lenfositik Lösemide PD-1/PD-L1 Ekspresyon Düzeyleri ve Prognostik Önemi
Authors : Ayfer GEDÜK, Özgür MEHTAP, Elif Birtaş ATEŞOĞLU, Pinar TARKUN, Esra TERZİ DEMİRSOY, Meral ULUKÖYLÜ MENGÜÇ, Serkan ÜNAL, Sinan MERSİN, Abdullah HACIHANEFİOĞLU, Tülin BURHANOĞLU, Gülçin GACAR
Pages : 197-203
Doi:10.31067/acusaglik.850893
View : 19 | Download : 3
Publication Date : 2021-04-01
Article Type : Research
Abstract :Purpose:In this study, we aimed to evaluate expression levels of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) and the effects on prognosis in chronic lymphocytic leukemia (CLL). Patients and Methods:92 patients who had flow cytometry from peripheral blood at the time of diagnosis were included in this study. The presence of PD-1/PD-L1 staining in 20% and above in lymphocytes was considered positive. Results:Median follow-up was 31 (1-114) months. PD-1 positivity was detected in 44 (47.8%), and PD-L1 positivity in 8 (8.7%) patients. The mean PD-1 level was 22.13% ± 15.39, and PD-L1 level was 8.4% ± 13.12 in all cohort. Overall survival rates were 69.1% in PD-1+ vs 79% in PD-1- groups and 75% in PD-L1+ vs 73.6% in the PD-L1- group in the 60th month (p=0.723, p=0.849 respectively). After first line treatment, partial response or better was observed in 18 (85.7%) patients in the PD-1- group and in 10 (71.4%) patients in the PD-1+ group (p=0.401). Median progression-free survival was 16 months [95% CI, 10.68-21.31] in the PD-1+ group, and 18 months [95% CI, 5.23-30.76] in the PD-1- group (p=0.432). In PD-1+ patients, time to next treatment was 2 (0-25) months, while in PD-1- patients it was determined as 7 (0-80) months (p=0.372). Conclusion:PD-1 expression was detected on lymphocytes in peripheral blood in CLL, however PD-L1 expression level was quite low. There was no clear effect of PD-1 and PD-L1 positivity on prognosisKeywords : programmed cell death 1, programmed cell death ligand 1, chronic lymphocytic leukemia